Literature DB >> 10229264

The effects of S-carboxymethylcysteine and N-acetylcysteine on the adherence of Moraxella catarrhalis to human pharyngeal epithelial cells.

C H Zheng1, K Ahmed, N Rikitomi, G Martinez, T Nagatake.   

Abstract

We investigated the effects of two mucoregulating drugs, S-carboxymethylcysteine (S-CMC) and N-acetylcysteine (NAC), on the attachment of Moraxella catarrhalis (M. catarrhalis) to pharyngeal epithelial cells. The attachment of M. catarrhalis decreased (33-57%) significantly (P<0.01) in a dose-dependent manner in cells treated with mucoregulating drugs as compared to the control. There was a significant (P<0.01) decrease (35-45%) in the attachment of M. catarrhalis to pharyngeal cells after oral administration of S-CMC. By electron microscopic observation, it was found that there was a fine, granular, electron-dense, ruthenium red-positive layer on the surface of pharyngeal epithelial cells; this layer was absent on cell surfaces treated with mucoregulating drugs. Possibly, this layer contained the portion of M. catarrhalis receptor which is responsible for the attachment of this bacteria to pharyngeal epithelial cells. From the above results, it may be concluded that one of the mechanisms of mucoregulating drugs to decrease the episode of respiratory infections in patients with chronic respiratory diseases is by inhibiting the attachment of bacteria to the upper respiratory tract.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10229264     DOI: 10.1111/j.1348-0421.1999.tb02381.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  9 in total

Review 1.  Antioxidant pharmacological therapies for COPD.

Authors:  Irfan Rahman; William MacNee
Journal:  Curr Opin Pharmacol       Date:  2012-02-18       Impact factor: 5.547

Review 2.  Pharmacological antioxidant strategies as therapeutic interventions for COPD.

Authors:  Irfan Rahman
Journal:  Biochim Biophys Acta       Date:  2011-11-09

3.  N-acetylcysteine, a novel treatment for Helicobacter pylori infection.

Authors:  Hien Quoc Huynh; Richard T L Couper; Cuong D Tran; Lynette Moore; Richard Kelso; Ross N Butler
Journal:  Dig Dis Sci       Date:  2004 Nov-Dec       Impact factor: 3.199

4.  N-acetyl-L-cysteine affects growth, extracellular polysaccharide production, and bacterial biofilm formation on solid surfaces.

Authors:  Ann-Cathrin Olofsson; Malte Hermansson; Hans Elwing
Journal:  Appl Environ Microbiol       Date:  2003-08       Impact factor: 4.792

5.  Synergistic effect of interleukin 1 alpha on nontypeable Haemophilus influenzae-induced up-regulation of human beta-defensin 2 in middle ear epithelial cells.

Authors:  Sung-Kyun Moon; Haa-Yung Lee; Huiqi Pan; Tamotsu Takeshita; Raekil Park; Kiweon Cha; Ali Andalibi; David J Lim
Journal:  BMC Infect Dis       Date:  2006-01-24       Impact factor: 3.090

Review 6.  Clinical Efficacy of Carbocysteine in COPD: Beyond the Mucolytic Action.

Authors:  Elisabetta Pace; Isa Cerveri; Donato Lacedonia; Gregorino Paone; Alessandro Sanduzzi Zamparelli; Rossella Sorbo; Marcello Allegretti; Luigi Lanata; Francesco Scaglione
Journal:  Pharmaceutics       Date:  2022-06-14       Impact factor: 6.525

Review 7.  The role for S-carboxymethylcysteine (carbocisteine) in the management of chronic obstructive pulmonary disease.

Authors:  C Hooper; J Calvert
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

Review 8.  Conventional and Nanotechnology Based Approaches to Combat Chronic Obstructive Pulmonary Disease: Implications for Chronic Airway Diseases.

Authors:  Mehak Passi; Sadia Shahid; Sankarakuttalam Chockalingam; Isaac Kirubakaran Sundar; Gopinath Packirisamy
Journal:  Int J Nanomedicine       Date:  2020-05-28

9.  A conservative treatment for chronic obstructive sialoadenitis by intraductal instillation of mucolytic, steroids and antibiotic solution.

Authors:  Francesco Lorusso; Angelo Immordino; Francesco Dispenza; Federico Sireci; Salvatore Gallina
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-06-10       Impact factor: 2.503

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.